Low postpandemic wave SARS‐CoV‐2 seroprevalence in Kuala Lumpur and Selangor, Malaysia
- 13 August 2020
- journal article
- letter
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (2) , 647-648
Abstract
Seroprevalence studies provide a more accurate picture of coronavirus disease 2019 (COVID‐19) than PCR‐confirmed cases as antibodies can be detected in mild or asymptomatic cases who otherwise remain undiagnosed. Seroprevalence can also be used as an indicator of population immunity.Keywords
All Related Versions
This publication has 6 references indexed in Scilit:
- Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020JAMA Internal Medicine, 2020
- Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence SettingThe Journal of Infectious Diseases, 2020
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interactionNature Biotechnology, 2020
- Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countriesJournal of Infection, 2020
- Serological differentiation between COVID-19 and SARS infectionsEmerging Microbes & Infections, 2020
- The Age-Specific Cumulative Incidence of Infection with Pandemic Influenza H1N1 2009 Was Similar in Various Countries Prior to VaccinationPLOS ONE, 2011